Mayank Mamtani
Stock Analyst at B. Riley Securities
(4.49)
# 262
Out of 4,944 analysts
126
Total ratings
46.85%
Success rate
34.66%
Average return
Main Sectors:
Stocks Rated by Mayank Mamtani
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NKTR Nektar Therapeutics | Maintains: Buy | $60 → $85 | $23.60 | +260.17% | 2 | Jul 8, 2025 | |
| MNOV MediciNova | Maintains: Buy | $6 → $5 | $1.30 | +284.62% | 2 | Jun 16, 2025 | |
| MGNX MacroGenics | Maintains: Neutral | $5 → $3 | $1.47 | +104.08% | 2 | May 20, 2025 | |
| MDGL Madrigal Pharmaceuticals | Reiterates: Buy | $422 → $460 | $359.00 | +28.13% | 12 | May 2, 2025 | |
| HROW Harrow | Maintains: Buy | $69 → $65 | $34.83 | +86.62% | 2 | Apr 1, 2025 | |
| VXRT Vaxart | Maintains: Buy | $2.5 → $2 | $0.38 | +426.32% | 6 | Mar 27, 2025 | |
| TRVI Trevi Therapeutics | Reiterates: Buy | $11 → $20 | $7.33 | +172.85% | 3 | Mar 19, 2025 | |
| LCTX Lineage Cell Therapeutics | Maintains: Buy | $4 → $3 | $1.01 | +197.03% | 2 | Mar 14, 2025 | |
| DNLI Denali Therapeutics | Reiterates: Buy | $38 → $35 | $13.22 | +164.75% | 2 | Mar 5, 2025 | |
| ARWR Arrowhead Pharmaceuticals | Reiterates: Buy | $51 → $38 | $17.80 | +113.48% | 7 | Feb 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $109 → $96 | $39.86 | +140.84% | 2 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $1 → $1.5 | $1.10 | +36.36% | 3 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 → $26 | $8.48 | +206.60% | 19 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $33 | $17.15 | +92.42% | 1 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $20 | $3.62 | +452.49% | 9 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $34 | $27.12 | +25.37% | 13 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $122 → $92 | $34.31 | +168.14% | 3 | Jun 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $140 | $17.67 | +692.30% | 1 | Oct 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $90 | $2.58 | +3,388.37% | 5 | Apr 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $160 | $4.81 | +3,226.40% | 1 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $11 → $5 | $1.53 | +226.80% | 3 | Aug 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $58 → $44 | $2.32 | +1,796.55% | 4 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $90 | $2.01 | +4,377.61% | 4 | Jul 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 → $7 | $2.42 | +189.26% | 3 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9,750 → $4,500 | $1.70 | +264,605.88% | 3 | Jan 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5,000 → $2,700 | $1.67 | +161,576.65% | 2 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $138 → $77 | $14.89 | +417.13% | 2 | Jan 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,980 → $1,440 | $1.42 | +101,308.45% | 3 | May 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $4 | $3.77 | +6.10% | 2 | Apr 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $47 → $39 | $96.58 | -59.62% | 2 | Mar 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $34 | $3.79 | +797.10% | 1 | Mar 13, 2020 |
Nektar Therapeutics
Jul 8, 2025
Maintains: Buy
Price Target: $60 → $85
Current: $23.60
Upside: +260.17%
MediciNova
Jun 16, 2025
Maintains: Buy
Price Target: $6 → $5
Current: $1.30
Upside: +284.62%
MacroGenics
May 20, 2025
Maintains: Neutral
Price Target: $5 → $3
Current: $1.47
Upside: +104.08%
Madrigal Pharmaceuticals
May 2, 2025
Reiterates: Buy
Price Target: $422 → $460
Current: $359.00
Upside: +28.13%
Harrow
Apr 1, 2025
Maintains: Buy
Price Target: $69 → $65
Current: $34.83
Upside: +86.62%
Vaxart
Mar 27, 2025
Maintains: Buy
Price Target: $2.5 → $2
Current: $0.38
Upside: +426.32%
Trevi Therapeutics
Mar 19, 2025
Reiterates: Buy
Price Target: $11 → $20
Current: $7.33
Upside: +172.85%
Lineage Cell Therapeutics
Mar 14, 2025
Maintains: Buy
Price Target: $4 → $3
Current: $1.01
Upside: +197.03%
Denali Therapeutics
Mar 5, 2025
Reiterates: Buy
Price Target: $38 → $35
Current: $13.22
Upside: +164.75%
Arrowhead Pharmaceuticals
Feb 14, 2025
Reiterates: Buy
Price Target: $51 → $38
Current: $17.80
Upside: +113.48%
Feb 7, 2025
Reiterates: Buy
Price Target: $109 → $96
Current: $39.86
Upside: +140.84%
Dec 19, 2024
Upgrades: Buy
Price Target: $1 → $1.5
Current: $1.10
Upside: +36.36%
Oct 10, 2024
Reiterates: Buy
Price Target: $23 → $26
Current: $8.48
Upside: +206.60%
Sep 19, 2024
Initiates: Buy
Price Target: $33
Current: $17.15
Upside: +92.42%
Aug 12, 2024
Reiterates: Buy
Price Target: $20
Current: $3.62
Upside: +452.49%
Aug 7, 2024
Maintains: Buy
Price Target: $29 → $34
Current: $27.12
Upside: +25.37%
Jun 4, 2024
Maintains: Buy
Price Target: $122 → $92
Current: $34.31
Upside: +168.14%
Oct 13, 2023
Initiates: Buy
Price Target: $140
Current: $17.67
Upside: +692.30%
Apr 10, 2023
Maintains: Buy
Price Target: $210 → $90
Current: $2.58
Upside: +3,388.37%
Mar 29, 2023
Reiterates: Buy
Price Target: $160
Current: $4.81
Upside: +3,226.40%
Aug 19, 2022
Downgrades: Neutral
Price Target: $11 → $5
Current: $1.53
Upside: +226.80%
Aug 11, 2022
Maintains: Buy
Price Target: $58 → $44
Current: $2.32
Upside: +1,796.55%
Jul 14, 2022
Maintains: Buy
Price Target: $120 → $90
Current: $2.01
Upside: +4,377.61%
May 24, 2022
Downgrades: Neutral
Price Target: $14 → $7
Current: $2.42
Upside: +189.26%
Jan 24, 2022
Maintains: Buy
Price Target: $9,750 → $4,500
Current: $1.70
Upside: +264,605.88%
Nov 30, 2021
Maintains: Buy
Price Target: $5,000 → $2,700
Current: $1.67
Upside: +161,576.65%
Jan 15, 2021
Downgrades: Neutral
Price Target: $138 → $77
Current: $14.89
Upside: +417.13%
May 22, 2020
Downgrades: Neutral
Price Target: $1,980 → $1,440
Current: $1.42
Upside: +101,308.45%
Apr 3, 2020
Maintains: Buy
Price Target: $8 → $4
Current: $3.77
Upside: +6.10%
Mar 18, 2020
Maintains: Buy
Price Target: $47 → $39
Current: $96.58
Upside: -59.62%
Mar 13, 2020
Maintains: Buy
Price Target: $43 → $34
Current: $3.79
Upside: +797.10%